Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. The results of clinical trials revea...
| Published in: | Chinese Journal of Lung Cancer |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | Chinese |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2017-02-01
|
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2017.02.09 |